STAR Infigratinib vs Gem/Cis Cholangio
A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301) Read More
Phase: III
PI/II Cholangiocarcinoma CX-4945 w Gem
A Phase I/II Study of CX-4945 in Combination with Gemcitabine plus Cisplatin in the Frontline Treatment of Patients with Cholangiocarcinoma (S4-13-001) Read More
Phase: II
Ph1/2 AMG510 KRAS mut G12C Solid Tumors
A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (20170543) Read More
Phase: II
STAR INCB054828 Urothelial FGF/FGFR
A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations(FIGHT-201)(INCB 54828-201) Read More
Phase: II
STAR Ph2 enfortumab (ASG-22CE)Urothelial
A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001 Read More
Phase: II
TALAZ IN GERMLINE BRCA1/2 MUT BC
(C3441020) A PHASE 2, NON-RANDOMIZED, OPEN LABEL, SINGLE ARM, MULTI-CENTER STUDY OF TALAZOPARIB FOR NEOADJUVANT TREATMENT OF GERMLINE BRCA1/2 MUTATION PATIENTS WITH EARLY TRIPLE-NEGATIVE BREAST CANCER Read More
Phase: II
A Double-Blind, Placebo-Controlled, Randomized Phase III Study Of Ipatasertib In Combination With Paclitaxel As A Treatment For Patients With PIK3CA/AKT1/PTEN-Altered, Locally Advanced Or Metastatic, Triple-Negative Breast Cancer Or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Phase: III
CONTESSA TRIO: Tes + PD-L1 HER2- LA/MBC
A Multicenter, Phase 2 Study of Tesetaxel plus Three Different PD-(L)1 Inhibitors in Patients with Triple-Negative, Locally Advanced orMetastatic Breast Cancer and Tesetaxel Monotherapy in Elderly Patients with HER2 Negative, Locally Advanced or Metastatic Breast Cancer (ODO-TE-B202) Read More
Phase: II
CONTESSA2: Ph2 HER2- HR+ BC
A Multinational, Multicenter, Phase 2 Study of Tesetaxel plus a Reduced Dose of Capecitabine in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Received a Taxane(ODO-TE-B201) Read More
Phase: II
Ph1 SGN-LIV1A Metastatic BC
A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with metastatic breast cancer (SGNLVA-001) Read More
Phase: I
Phase 1/2a BMS-986253 + Nivo
A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002) Read More
Phase: I/II
Ph1b Abemaciclib + SOC in mBC
A Phase 1b Study of Abemaciclib in Combination with Therapies for Patients with Metastatic Breast Cancer (I3Y-MC-JPBH) Read More
Phase: I
Ph3 Pembro HR+/HER2- BC
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK3475-KN756) Read More
Phase: III
Ph2 alpelisib+fulves/letrozole HR+ HER2-
BYLieve: A phase II, multicenter, open-label, three-cohort, noncomparative study to assess the efficacy and safety of alpelisib plus fulvestrant or letrozole in patients with PIK3CA mutant,hormone receptor (HR) positive, HER2-negative advanced breast cancer (aBC), who have progressed on or after prior treatments (CBYL719X2402) Read More
Phase: II
FLEX Registry: Evaluate New Gene Express
MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry) Read More
Neoadjuvant Phase II Study of Pembrolizumab and Carboplatin plus Docetaxel in Triple Negative Breast Cancer (NeoPACT)
Phase: II
Phase 1/2, Multicenter, Non-randomized, Open-label, Multiple-Dose First-in-human Study of U3-1402, in Subjects With HER3 Positive Metastatic Breast Cancer
Phase: II
Ph 1b2 LIV1A+Pembro 1L mTNBC
Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A inCombination with Pembrolizumab for First-Line Treatment ofPatients with Unresectable Locally-Advanced or MetastaticTriple-Negative Breast Cancer (SGNLVA-002) Read More
Phase: I/II
Ph3 SYD985 HER2+ unresect adv/mBC
SYD985.002: A multi-centre, open-label, randomized clinical trial comparing the efficacy and safety of the antibody-drug conjugate SYD985 to physician''s choice in patients with HER2-positive unresectable locally advanced or metastatic breast cancer Read More
Phase: III
Ph1/2 AMG510 KRAS mut G12C Solid Tumors
A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (20170543) Read More
Phase: II
Phase 1/2a BMS-986253 + Nivo
A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002) Read More
Phase: I/II
Ph 2 Regorafenib + Anti-PD-1 MSS CRC
An Open-label, Single-arm, Phase II Study of Regorafenib and Nivolumab in Patients With Mismatch Repair-Proficient (pMMR)/Microsatellite Stable (MSS) Colorectal Cancer (CRC)(20975) Read More
Phase: II
Ph3 2L DCC-2618 vs sunitinib GIST
(DCC-2618-03-002) A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of DCC-2618 vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumors after Treatment with Imatinib Read More
Phase: III
Ph3 BLU-285 vs Regorafenib GIST
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST) Read More
Phase: III
Ph 1/1b Immunotherapy Combo in NSCLC
(AB928CSP0004) A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Lung Cancer Read More
Phase: I
Ph 3 Sit+Nivo vs. Docetaxel NSCLC
516-005: A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy in Combination with Checkpoint Inhibitor Therapy Read More
Phase: III
Ph1/2 AMG510 KRAS mut G12C Solid Tumors
A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (20170543) Read More
Phase: II
Phase 1/2a BMS-986253 + Nivo
A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002) Read More
Phase: I/II
STAR Ph3 Peme+PltChem+/-Pemb NSCLC TKI
A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + PlatinumChemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789) Read More
Phase: III
Atezo Rollover for GNE & Roche
BO39633 (IMbrella A), An open-Label, Multicenter Extension and Long-Term Observational Study in Patients Previously Enrolled in A Genentech- and/or F.Hoffman-La Roche Ltd. sponsored Atezolizumab Study Read More
Phase: II/III
STAR Ph3 ALK+ mNSCLC (Brigatinib-3001)
Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG™) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®) Read More
Phase: III
STAR BV in older pts w/1L cHL or PTCL
A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in adults age 60 and above Read More
Phase: II
Ph1 INCB050465 B-Cell (CITADEL-112)
INCB 50465-112: A Phase 1, Open-Label, Dose-Finding Study of INCB050465 in Combination With Investigator Choice of Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112) Read More
Phase: I
Ph1/2 AMG510 KRAS mut G12C Solid Tumors
A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (20170543) Read More
Phase: II
Phase 1/2a BMS-986253 + Nivo
A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002) Read More
Phase: I/II
A Phase IIa, Multicenter, Open-label, Study to Assess the Safety and Efficacy of the Combination of BL-8040 and Pembrolizumab in Subjects with Metastatic Pancreatic Cancer (the COMBAT study)
Phase: IIa
PANOVA-3: 1L Gemcit + nab-pac pancreatic
PANOVA-3: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma (EF-27) Read More
Phase: III
STAR Abirat+pred +/- abemaciclib mCRPC
A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM) Read More
Phase: II
STAR Ph2 Rucaparib mCRPC (TRITON 2)
TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052 Read More
Phase: II
STAR Rucaparib v PhysC mCRPC (TRITON3)
TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063) Read More
Phase: III
STAR Ph2 Pemigatinib Solids FGFR
(INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) Read More
Phase: II
STAR Ph2 Pemigatinib Solids FGFR
(INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) Read More
Phase: II
Ph1/2 FIH BMS-986249 + Nivo Solid Tumor
A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors Read More
Phase: I
Ph1/2 AMG510 KRAS mut G12C Solid Tumors
A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (20170543) Read More
Phase: II
A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors
Phase: I/II
Phase 1/2a BMS-986253 + Nivo
A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002) Read More
Phase: I/II
A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
Phase: Ib
Phase 1b Multicohort Study of Anetumab Ravtansine for Mesothelin-Positive Advanced Solid Tumors (Study No 15834) in multiple indications (NSCLC, Thymic cancer, Triple negative breast cancer, gastric cancer, cholangiocarcinoma and pancreatic cancer)
Phase: Ib
STAR Ph3 FGFR erdafitinib urothelial
(42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR) Read More
Phase: III
STAR Ph3 FGFR erdafitinib urothelial
(42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR) Read More
Phase: III
Phase 1/2a BMS-986253 + Nivo
A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002) Read More
Phase: I/II
STAR INCB054828 Urothelial FGF/FGFR
A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations(FIGHT-201)(INCB 54828-201) Read More
Phase: II
STAR Ph2 enfortumab (ASG-22CE)Urothelial
A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001 Read More
Phase: II